Compare · CERE vs QS
CERE vs QS
Side-by-side comparison of Cerevel Therapeutics Holdings Inc. (CERE) and QuantumScape Corporation (QS): market cap, price performance, sector, and recent activity on the wire.
Summary
- CERE operates in Health Care, while QS operates in Miscellaneous - the two are in different parts of the market.
- QS is the larger of the two at $6.09B, about 1.7x CERE ($3.50B).
- QS has hit the wire 7 times in the past 4 weeks while CERE has been quiet.
- QS has more recent analyst coverage (22 ratings vs 19 for CERE).
- Company
- Cerevel Therapeutics Holdings Inc.
- QuantumScape Corporation
- Price
- $44.97+0.81%
- $4.88-4.50%
- Market cap
- $3.50B
- $6.09B
- 1M return
- -
- -31.56%
- 1Y return
- -
- -55.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 0
- 7
- Recent ratings
- 19
- 22
Cerevel Therapeutics Holdings Inc.
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
QuantumScape Corporation
QuantumScape Corporation, a development stage company, engages in the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. The company was founded in 2010 and is headquartered in San Jose, California.
Latest CERE
- Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
- SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.
- Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)
- Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.
- Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)
- Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest QS
- SEC Form 10-Q filed by QuantumScape Corporation
- QuantumScape Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- QuantumScape Reports Second Quarter 2026 Business and Financial Results
- QuantumScape Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- QuantumScape Announces Timing of Second Quarter 2026 Business Results and Webcast
- CHIEF TECHNOLOGY OFFICER Holme Timothy converted options into 137,245 shares and sold $999,566 worth of shares (137,245 units at $7.28) as part of a pre-agreed trading plan (SEC Form 4)
- CHIEF FINANCIAL OFFICER Hettrich Kevin sold $71,362 worth of shares (9,800 units at $7.28) as part of a pre-agreed trading plan, decreasing direct ownership by 0.54% to 1,816,257 units (SEC Form 4)
- CHIEF FINANCIAL OFFICER Hettrich Kevin sold $77,811 worth of shares (9,800 units at $7.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.53% to 1,826,057 units (SEC Form 4)
- QuantumScape Announces Agreement with Honda on Solid-State Battery Technology
- SEC Form 144 filed by QuantumScape Corporation